Baird Medical Investment Holdings Limited
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Baird Medical Investment Holdings Limited (Nasdaq: BDMD) is a technology-driven medical device company that develops, manufactures, and sells minimally invasive instruments and devices for the treatment of thyroid diseases, including thyroid radiofrequency ablation (RFA) systems, microwave ablation (MWA) systems, and vascular access products; its flagship product, the Monopolar Radio-Frequency Ablation System (RFA 2000 series), utilizes vacuum-assisted technology for precise nodule detection and thermal ablation, while complementary offerings include the Bipolar Radiofrequency Ablation System (RFA 3000 series), microwave ablation generators, disposable electrodes, puncture needles, and biopsy needles. The company serves healthcare providers and patients seeking non-surgical alternatives to thyroidectomy, primarily targeting markets in China, with expanding operations in Asia and select international regions. Founded in 2013 and headquartered in Changsha, Hunan Province, China, Baird Medical operates through subsidiaries focused on research, production, and commercialization of ablation technologies in the interventional oncology segment. In recent developments, Baird Medical completed its initial public offering on Nasdaq in January 2024, raising approximately $43.5 million to fuel R&D, manufacturing expansion, and global market penetration; the company also secured strategic distribution partnerships in Southeast Asia and Europe during 2024-2025 to broaden access to its RFA platforms. Additionally, it launched enhancements to its MWA product line in mid-2025, incorporating AI-assisted imaging for improved procedural accuracy, and announced a manufacturing facility upgrade in Hunan Province to meet rising demand amid China's growing preference for minimally invasive thyroid treatments. These initiatives reflect Baird Medical's shift toward international scaling while reinforcing its leadership in ultrasound-guided thermal ablation solutions.
Company News
Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
Baird Medical Investment (NASDAQ:BDMD) Trading Down 2.5% – Should You Sell?
Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan
Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally
Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina
Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion
Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update
Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia
Baird Medical Expands Global Reach with Regulatory Clearance in Argentina
Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026
Baird Medical Accelerates Global Registration of AI-Driven Surgical Software
Baird Medical Accelerates U.S. Expansion at NASOIE 2026
Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology
Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences
Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital
Baird Medical Accelerates Global Commercial Roadmap with Strategic Clinical Education Initiatives in the U.S. and Japan
Baird Medical Successfully Concludes Gynecology Microwave Ablation Masterclass
Baird Medical Accelerates Global Commercial Roadmap through Strategic Partnership with Stonewood Key Capital
Baird Medical Highlights Strategic Engagement at 2026 J.P. Morgan Healthcare Conference
Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam